Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year

AIMS: Dapagliflozin and exenatide reduce body weight by differing mechanisms. Dual therapy with these agents reduces body weight, adipose tissue volume, glycaemia and systolic blood pressure (SBP) over 24 weeks. Here, we examined these effects over 1 year in obese adults without diabetes. MATERIALS...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Diabetes Obes Metab
Auteurs principaux: Lundkvist, Per, Pereira, Maria J., Katsogiannos, Petros, Sjöström, C. David, Johnsson, Eva, Eriksson, Jan W.
Format: Artigo
Langue:Inglês
Publié: Blackwell Publishing Ltd 2017
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5575470/
https://ncbi.nlm.nih.gov/pubmed/28345814
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12954
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires